Doane, Michael J.
Bessonova, Leona
Friedler, Haley S.
Mortimer, Kathleen M.
Cheng, Harry
Brecht, Thomas
O’Sullivan, Amy K.
Cummings, Hannah
McDonnell, David
Meyer, Jonathan M.
Article History
Received: 20 August 2021
Accepted: 31 January 2022
First Online: 14 February 2022
Declarations
:
: All database records were de-identified and certified to be fully compliant with US patient confidentiality requirements set forth in the Health Insurance Portability and Accountability Act (HIPAA) of 1996. Because this study used only de-identified patient records and did not involve the collection, use, or transmittal of individually identifiable data, it was exempt from institutional review board approval.
: Not applicable.
: MJD, AKO, and HC are employees of Alkermes, Inc. DM is an employee of Alkermes Pharma Ireland Ltd. LB was an employee of Alkermes, Inc. at the time this study was conducted. HSF, KMM, HC, and TB are employees of OM1, Inc., which contracted with Alkermes, Inc. to access these data and complete these analyses. JMM served as a speaker or advisor for Acadia Pharmaceuticals, Alkermes, Inc., Allergan (AbbVie), Intra-Cellular Therapies, Neurocrine, Noven, Otsuka America, Inc., Sunovion Pharmaceuticals, and Teva Pharmaceutical Industries Ltd.